TP53 and neoplasm: Additionally, patients with high HOXC6 expression showed poorer response to PD-1 inhibitors, while those with low HOXC6 expression exhibited higher APC/TP53 mutation burden, suggesting HOXC6 may promote tumor progression through mutation-independent transcriptional regulatory mechanisms.